Dosage form suitability in vulnerable populations: A focus on paracetamol acceptability from infants to centenarians.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2019
2019
Historique:
received:
31
10
2018
accepted:
04
08
2019
entrez:
21
8
2019
pubmed:
21
8
2019
medline:
3
4
2020
Statut:
epublish
Résumé
Medicine acceptability is a multi-faceted concept driven by both product and user characteristics. Although a key factor for treatment effectiveness, especially in vulnerable populations, knowledge of those medicine features that best promote individual user acceptability remains fragmented. Focusing on paracetamol, this study has explored the appropriateness of pharmaceutical products in different dosage forms to achieve adequate patient acceptability from infants to centenarians. This observational, multicentre, prospective study was carried out in 10 hospitals, 8 nursing homes and over 150 community dispensaries. Observers reported several behaviours/events evaluating acceptability for 1016 different pharmaceutical product uses in paediatrics (<18y.) and 1288 in the elderly (≥65y.). Using mapping and clustering, a multivariate approach offered an intelligible reference framework for each population, providing comprehensive scores: positively or negatively accepted. Among all the evaluations supporting the acceptability reference frameworks, there were 502 reports on paracetamol products intake. Herein we focused on the 5 products with ≥30 evaluations. Although oral suspension and powder for oral solution were positively-accepted in the paediatric group, the powder had a higher rate of negative patient reaction (p<0.001). Of those that received this formulation, 72% were ≤8y., and therefore suitable to receive the better accepted oral suspension. In the elderly, patients with swallowing disorders were preferentially treated with such powders (p<0.001), which were less often fully taken than orally disintegrating tablets (p<0.001). Even in those patients ≥90y., capsule formulations appeared to be the best accepted product in patients without swallowing alterations, and thus could be a suitable alternative to the powder in this population. By better integrating patient characteristics when choosing dosage forms, clinicians and caregivers may improve treatment acceptability and adherence. Moreover, hospitals and healthcare institutions could optimise purchasing to best suit their local population, disseminating information to help staff align specific dosage forms to targeted patients.
Identifiants
pubmed: 31430323
doi: 10.1371/journal.pone.0221261
pii: PONE-D-18-28685
pmc: PMC6701828
doi:
Substances chimiques
Dosage Forms
0
Acetaminophen
362O9ITL9D
Types de publication
Journal Article
Multicenter Study
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0221261Déclaration de conflit d'intérêts
The authors have read the journal’s policy and the authors of this paper have the following competing interests: FR and TV are paid employees of ClinSearch. This alters our adherence to PLOS ONE policies on sharing data and materials. Please see the Data Availability statement for further information. There are no patents, products in development or marketed products to declare.
Références
Clin Pediatr (Phila). 1965 Mar;4:137-40
pubmed: 14264991
Health Qual Life Outcomes. 2006 Oct 11;4:79
pubmed: 17034633
Int J Pharm. 2012 Jul 1;430(1-2):197-206
pubmed: 22525080
Value Health. 2013 Jun;16(4):461-79
pubmed: 23796280
BMJ. 2013 Nov 26;347:f6954
pubmed: 24284017
Drugs. 2014 Oct;74(16):1871-1889
pubmed: 25274536
J Pharm Pharmacol. 2017 Apr;69(4):406-416
pubmed: 27109018
J Pharm Pharmacol. 2017 Apr;69(4):361-376
pubmed: 27524471
Int J Pharm. 2017 Apr 15;521(1-2):294-305
pubmed: 28229945
Int J Pharm. 2018 Feb 5;536(2):547-562
pubmed: 28705619
J Pharm Sci. 2017 Nov;106(11):3188-3198
pubmed: 28734784
J Hepatol. 2017 Dec;67(6):1324-1331
pubmed: 28734939
J Pharm Pharmacol. 2018 Jan;70(1):42-50
pubmed: 29072321
Drug Discov Today. 2018 Apr;23(4):830-847
pubmed: 29371123
Pharm Res. 2018 May 7;35(7):136
pubmed: 29736594
Eur J Hosp Pharm. 2016 Jul;23(4):187-188
pubmed: 31156845